Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
2,656
Views
4
CrossRef citations to date
0
Altmetric
Migraine

Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials

Joshua Tobina Neurosciences Clinic, Banner University Medical Center, Phoenix, AZ, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0564-859X
ORCID Icon,
Janet H. Fordb Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
Antje Tockhorn-Heidenreichc Eli Lilly and Company, Bracknell, UK
,
Russell M. Nicholsb Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
Wenyu Yeb Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
Rohit Bhandarib Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
,
Xiaojuan Mib Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA;d TechData Service Company, King of Prussia, PA, USA
,
Karan Sharmab Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
&
Richard B. Liptone Albert Einstein College of Medicine, Bronx, NY, USA
 show all
Pages 630-639 | Received 20 Jan 2022, Accepted 26 Apr 2022, Published online: 17 May 2022

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Oralee J. Varnado, Wenyu Ye, Xiaojuan Mi, Russel Burge & Jerry Hall. (2023) Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States. Journal of Medical Economics 26:1, pages 149-157.
Read now

Articles from other publishers (3)

Carlos Lazaro-Hernandez, Edoardo Caronna, Joana Rosell-Mirmi, Victor J Gallardo, Alicia Alpuente, Marta Torres-Ferrus & Patricia Pozo-Rosich. (2024) Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population. The Journal of Headache and Pain 25:1.
Crossref
Matilde Leonardi, Paolo Martelletti, Rami Burstein, Arianna Fornari, Licia Grazzi, Alla Guekht, Richard B. Lipton, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Elena Ruiz De la Torre, Simona Sacco, Timothy J. Steiner, Nirmal Surya, Takao Takeshima, Cristina Tassorelli, Shuu-Jiun Wang, Tissa Wijeratne, Shengyuan Yu & Alberto Raggi. (2024) The World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders and the headache revolution: from headache burden to a global action plan for headache disorders. The Journal of Headache and Pain 25:1.
Crossref
Délia Szok, Anett Csáti, László Vécsei & János Tajti. (2023) Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review. Life 13:3, pages 665.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.